Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02559401
Other study ID # UPCC 42313
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 2014
Est. completion date July 7, 2022

Study information

Verified date April 2023
Source Abramson Cancer Center at Penn Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Currently, standard-of-care tractography is based on information obtained from diffusion tensor imaging (DTI). DTI is a diffusion magnetic resonance imaging (dMRI) technique that is routinely obtained on neurosurgical patients to assist in pre-operative planning. The primary objective of the proposed study is to determine the ability of msHARDI-based tractography to discern fibers in edematous brain regions.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date July 7, 2022
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - brain lesions, including but not limited to tumors, epileptic foci, and vascular abnormalities, in or around eloquent brain regions (i.e., motor, language); - clinical need for pre-operative 'advanced imaging' (which includes conventional DTI); - age between 18-80 years of age; - male or female gender. Eloquent regions include: Temporal and frontal lobes (speech/language); bilateral occipital lobes (vision); bilateral parietal lobes (sensation); and bilateral motor cortex (movement). Exclusion Criteria: - a contraindication for obtaining an MRI scan (e.g. implanted devices, retrained foreign body) - pregnancy - absence of the capacity to make medical decisions or provide informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRI

Neurocognitive battery


Locations

Country Name City State
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects providing completion of the neurocognitive battery 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT01254500 - To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions N/A
Completed NCT01304576 - Orientation Agnosia: Clinical and Anatomical Study N/A
Completed NCT00907530 - Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain Phase 4
Terminated NCT02187822 - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Phase 1
Withdrawn NCT02328300 - FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Recruiting NCT01849549 - Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage N/A
Completed NCT03528200 - DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques N/A